Literature DB >> 34302619

Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy.

Yin Qianmei1, Su Zehong1,2, Wang Guang1, Li Hui1, Gaojian Lian3.   

Abstract

Th17 and Treg cells play an important role in regulating tissue inflammation and maintaining the stability of the immune system. They regulate inflammatory responses, participate in the occurrence and development of autoimmune diseases and tumors, and determine the disease progress. Malignant tumor is one of the diseases with the highest mortality rate in the world. However, the efficacy of traditional treatment is limited, so it is necessary to find safe and efficient treatment methods. Studies have shown that the balance of Th17/Treg cells plays a critical role in tumor progression. In this paper, we review the antitumor and tumor-suppressing effects of Th17/Treg cells, and new strategies for tumor therapy, combined with new research hotspots such as immune checkpoint therapy, miRNA-related gene therapy, and metabolic pathway regulation of Th17/Treg cell differentiation and tumor generation. The synergistic therapy is expected to be widely used in the future clinical practice, providing a new choice for the prevention and treatment of malignant tumors.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer treatment; Immune checkpoint therapy; Metabolic regulation; Th17 cells; Treg cells

Mesh:

Substances:

Year:  2021        PMID: 34302619     DOI: 10.1007/s12026-021-09211-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  142 in total

1.  Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression.

Authors:  Fanny Chalmin; Grégoire Mignot; Mélanie Bruchard; Angélique Chevriaux; Frédérique Végran; Aziz Hichami; Sylvain Ladoire; Valentin Derangère; Julie Vincent; David Masson; Simon C Robson; Gerard Eberl; Jean René Pallandre; Christophe Borg; Bernhard Ryffel; Lionel Apetoh; Cédric Rébé; Francois Ghiringhelli
Journal:  Immunity       Date:  2012-03-08       Impact factor: 31.745

2.  Development, cytokine profile and function of human interleukin 17-producing helper T cells.

Authors:  Nicholas J Wilson; Katia Boniface; Jason R Chan; Brent S McKenzie; Wendy M Blumenschein; Jeanine D Mattson; Beth Basham; Kathleen Smith; Taiying Chen; Franck Morel; Jean-Claude Lecron; Robert A Kastelein; Daniel J Cua; Terrill K McClanahan; Edward P Bowman; Rene de Waal Malefyt
Journal:  Nat Immunol       Date:  2007-08-05       Impact factor: 25.606

3.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells.

Authors:  Eva V Acosta-Rodriguez; Giorgio Napolitani; Antonio Lanzavecchia; Federica Sallusto
Journal:  Nat Immunol       Date:  2007-08-05       Impact factor: 25.606

4.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

5.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17.

Authors:  Heon Park; Zhaoxia Li; Xuexian O Yang; Seon Hee Chang; Roza Nurieva; Yi-Hong Wang; Ying Wang; Leroy Hood; Zhou Zhu; Qiang Tian; Chen Dong
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

6.  Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.

Authors:  Sudeepta Aggarwal; Nico Ghilardi; Ming-Hong Xie; Frederic J de Sauvage; Austin L Gurney
Journal:  J Biol Chem       Date:  2002-11-03       Impact factor: 5.157

7.  TGF-beta promotes Th17 cell development through inhibition of SOCS3.

Authors:  Hongwei Qin; Lanfang Wang; Ting Feng; Charles O Elson; Sandrine A Niyongere; Sun Jung Lee; Stephanie L Reynolds; Casey T Weaver; Kevin Roarty; Rosa Serra; Etty N Benveniste; Yingzi Cong
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

8.  Induction and stability of human Th17 cells require endogenous NOS2 and cGMP-dependent NO signaling.

Authors:  Nataša Obermajer; Jeffrey L Wong; Robert P Edwards; Kong Chen; Melanie Scott; Shabaana Khader; Jay K Kolls; Kunle Odunsi; Timothy R Billiar; Pawel Kalinski
Journal:  J Exp Med       Date:  2013-07-01       Impact factor: 14.307

Review 9.  Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape.

Authors:  François Ghiringhelli; Mélanie Bruchard; Fanny Chalmin; Cédric Rébé
Journal:  J Biomed Biotechnol       Date:  2012-10-14

10.  IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3.

Authors:  Reiner K W Mailer; Anne-Laure Joly; Sang Liu; Szabolcs Elias; Jesper Tegner; John Andersson
Journal:  Sci Rep       Date:  2015-10-06       Impact factor: 4.379

View more
  5 in total

1.  Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma.

Authors:  Zhi-Yong Shi; Sheng-Xiao Zhang; Di Fan; Cai-Hong Li; Zhe-Hao Cheng; Yan Xue; Li-Xiang Wu; Ke-Yi Lu; Su-Yun Yang; Yan Cheng; Zhi-Fang Wu; Chong Gao; Xiao-Feng Li; Hai-Yan Liu; Si-Jin Li
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

2.  MSLN Correlates With Immune Infiltration and Chemoresistance as a Prognostic Biomarker in Ovarian Cancer.

Authors:  Yike Li; Wanjia Tian; Hong Zhang; Zhijian Zhang; Qinghe Zhao; Lei Chang; Ningjing Lei; Weiwei Zhang
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

3.  Preliminary Study on the Imbalance Between Th17 and Regulatory T Cells in Antiphospholipid Syndrome.

Authors:  Huanhuan Yan; Baochen Li; Rui Su; Chong Gao; Xiaofeng Li; Caihong Wang
Journal:  Front Immunol       Date:  2022-05-06       Impact factor: 8.786

Review 4.  Vitamin D, Th17 Lymphocytes, and Breast Cancer.

Authors:  Beata Filip-Psurska; Honorata Zachary; Aleksandra Strzykalska; Joanna Wietrzyk
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

Review 5.  Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy.

Authors:  Ming Zhang; Tingju Wei; Xiaodan Zhang; Danfeng Guo
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.